Pharmacotherapy for gastric and intestinal cramping pain: Current and emerging therapies
This article will explore relevant literature from respected databases such as PubMed, Scopus, Google Scholar, Cochrane Library, and Web of Science. Additionally, we searched ClinicalTrials.gov and the WHO ICTRP database for the latest clinical trials.EXPERT OPINION: Consensus dictates that antispasmodics such as hyoscine-N-butyl bromide and mebeverine should be the primary treatment for GICP. If these prove ineffective, patients can switch to an antispasmodic with a different mode of action or add acetaminophen/NSAIDs for more severe cases. Currently, several antispasmodics are undergoing clinical trials, including drotav...
Source: Expert Opinion on Pharmacotherapy - October 3, 2023 Category: Drugs & Pharmacology Authors: Taraneh Mousavi Mohammadhossein Sharifnia Shekoufeh Nikfar Mohammad Abdollahi Source Type: research
An update on the pharmacotherapeutic strategies for the treatment of dysthymic disorder: a systematic review
Expert Opin Pharmacother. 2023 Oct 3:1-6. doi: 10.1080/14656566.2023.2265809. Online ahead of print.ABSTRACTINTRODUCTION: Longer treatment times, more comorbidity, more severe impairments in social, psychological, and emotional functioning, increased healthcare use, and more hospitalizations are all factors that are related to dysthymia. Given the significant prevalence of dysthymia (including persistent depressive disorder) worldwide, its comorbidity with several mental disorders, and the detrimental effects of these comorbidities, it is important to conduct a systematic review to compare the effects of pharmacological ac...
Source: Expert Opinion on Pharmacotherapy - October 3, 2023 Category: Drugs & Pharmacology Authors: Laiana A Quagliato Diego Primavera Michele Fornaro Antonio Preti Mauro G Carta Antonio E Nardi Source Type: research
Future treatment of vascular calcification in chronic kidney disease
Expert Opin Pharmacother. 2023 Sep 30. doi: 10.1080/14656566.2023.2266381. Online ahead of print.ABSTRACTINTRODUCTION: Cardiovascular disease (CVD) is one of the global leading causes of morbidity and mortality in chronic kidney disease (CKD) patients. Vascular calcification (VC) is a major cause of CVD in this population and is the consequence of complex interactions between inhibitor and promoter factors leading to pathological deposition of calcium and phosphate in soft tissues. Different pathological landscapes are associated with the development of VC, such as endothelial dysfunction, oxidative stress, chronic inflamm...
Source: Expert Opinion on Pharmacotherapy - September 30, 2023 Category: Drugs & Pharmacology Authors: Mario Cozzolino Federico Maffei Faccioli Anila Cara Giulia Boni Brivio Francesca Rivela Paola Ciceri Lorenza Magagnoli Andrea Galassi Simona Barbuto Serena Speciale Carlo Minicucci Giuseppe Cianciolo Source Type: research
Current optimal pharmacologic therapies for Overactive bladder
Expert Opin Pharmacother. 2023 Sep 26. doi: 10.1080/14656566.2023.2264183. Online ahead of print.ABSTRACTINTRODUCTION: Overactive bladder (OAB) is a common syndrome in adults. Current pharmacologic treatment includes antimuscarinic agents and β-3 adrenoceptor agonists. For non-responders to oral medication, intravesical injection of botulinum toxin A (BoNT-A) is an effective option. However, these treatments have potential adverse events and should be cautiously selected for appropriate patients. This review presents the recently published results of clinical trials and studies for patients with OAB and the underlying pat...
Source: Expert Opinion on Pharmacotherapy - September 26, 2023 Category: Drugs & Pharmacology Authors: Yuan-Hong Jiang Hann-Chorng Kuo Source Type: research
Paxlovid as a potential treatment for long COVID
Expert Opin Pharmacother. 2023 Sep 21:1-5. doi: 10.1080/14656566.2023.2262387. Online ahead of print.ABSTRACTINTRODUCTION: On 31 July 2023, the United States Department of Health and Human Services announced the formation of the Office of Long COVID Research and Practice and the United States National Institutes of Health opened enrollment for RECOVER-Vital, a randomized study to evaluate new treatment options for long Coronavirus (long COVID).AREAS COVERED: The RECOVER Initiative is a $1.15 billion research platform intended to describe, categorize, treat, and prevent long-term symptoms following infection by Severe Acute...
Source: Expert Opinion on Pharmacotherapy - September 21, 2023 Category: Drugs & Pharmacology Authors: Matthew W McCarthy Source Type: research
Paxlovid as a potential treatment for long COVID
Expert Opin Pharmacother. 2023 Sep 21. doi: 10.1080/14656566.2023.2262387. Online ahead of print.ABSTRACTINTRODUCTION: On 31 July 2023, the United States Department of Health and Human Services announced the formation of the Office of Long COVID Research and Practice and the United States National Institutes of Health opened enrollment for RECOVER-Vital, a randomized study to evaluate new treatment options for long Coronavirus (long COVID).AREAS COVERED: The RECOVER Initiative is a $1.15 billion research platform intended to describe, categorize, treat, and prevent long-term symptoms following infection by Severe Acute Res...
Source: Expert Opinion on Pharmacotherapy - September 21, 2023 Category: Drugs & Pharmacology Authors: Matthew W McCarthy Source Type: research
FGFR Inhibitor Resistance in cholangiocarcinoma: Current understanding and future directions
Expert Opin Pharmacother. 2023 Sep 14. doi: 10.1080/14656566.2023.2259802. Online ahead of print.NO ABSTRACTPMID:37710362 | DOI:10.1080/14656566.2023.2259802 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - September 15, 2023 Category: Drugs & Pharmacology Authors: Daniel Neureiter Peter Ellinghaus Matthias Ocker Source Type: research
